LAB - 7.4 - Thrombolytics and Antiplatelets Flashcards
The general action of thrombolytic agents is the
selective degradation of formed fibrin clots with minimal effect on clot formation.
This is administered for disorders in which an intravascular clot has already formed such as in acute myocardial infarction, pulmonary embolism, acute ischemic cerebrovascular accident (CVA), and deep vein thrombosis (DVT )
Thrombolytics
Thrombolytics are administered for disorders in which an intravascular clot has already formed such as in
acute myocardial infarction, pulmonary embolism, acute ischemic cerebrovascular accident (CVA), and deep vein thrombosis (DVT )
Thrombolytics are used early in the course of myocardial infarction within ___ hours of the onset of the infarct to restore blood flow
4 to 6
Thrombolytics time limitation is not related to drug activity, because thrombolytic agents can break down clots older than ___ hours.
6
Rather, tissue that has been anoxic for more than 6 hours is not likely to benefit from thrombolytic therapy, making the risks to the client greater than the advantages.
NA
The goal of thrombolytic therapy is to quickly restore blood flow to the tissue served by the blocked vessel.
NA
Contraindications for thrombolytics
active internal bleeding, history of CVA, intracranial problems, trauma within the previous 2 months
Examples of Thrombolytics
Alteplase
Streptokinase
Fondaparinux (Arixtra)
If this thrombolytic is administered within 3 hours of onset of ischemic stroke, it significantly improves clinical outcomes especially the patient’s ability to perform activities of daily living
Alteplase
Adverse effects Alteplase
Bleeding complications including GI and cerebral hemorrhages
This thrombolytic’s therapy is instituted within 4 hours of myocardial infarction and is infused for one hour
Streptokinase
Streptokinase therapy is instituted within ___ hours of myocardial infarction and is infused for ___ hour
4
1
For Streptokinase, Thromboplastin time is monitored and maintained at ___ fold the control value
2-5
this is a specific blocker of factor Xa for the prevention of venous thromboembolic events in patients undergoing surgery for hip fracture, hip or knee replacement.
Fondaparinux (Arixtra)